发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy. 优化检查点靶向抗癌疗法前景的策略。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-05-08 DOI: 10.1080/1750743X.2024.2343271
Bernardo L Rapoport, Ronald Anderson
{"title":"Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy.","authors":"Bernardo L Rapoport, Ronald Anderson","doi":"10.1080/1750743X.2024.2343271","DOIUrl":"10.1080/1750743X.2024.2343271","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"565-568"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Helminth-derived biomolecules as potential therapeutics against ulcerative colitis. 螺旋虫衍生生物大分子作为溃疡性结肠炎的潜在疗法。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2360382
Ankita Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee
{"title":"Helminth-derived biomolecules as potential therapeutics against ulcerative colitis.","authors":"Ankita Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee","doi":"10.1080/1750743X.2024.2360382","DOIUrl":"10.1080/1750743X.2024.2360382","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"635-640"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study. 肺癌患者胰腺特异性免疫相关不良事件：病例系列研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2354108
Liu Jia, Shi Yuequan, Fang Jian, Lu Hongmin, Shui Yongjie, Liu Xiaoyan, Chen Minjiang, Xu Yan, Wang Mengzhao
{"title":"Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study.","authors":"Liu Jia, Shi Yuequan, Fang Jian, Lu Hongmin, Shui Yongjie, Liu Xiaoyan, Chen Minjiang, Xu Yan, Wang Mengzhao","doi":"10.1080/1750743X.2024.2354108","DOIUrl":"10.1080/1750743X.2024.2354108","url":null,"abstract":"<p><p>Immune-related adverse events (irAEs) are one of the key concerns in cancer patients treated with immune checkpoint inhibitors (ICIs). Among the various irAEs, pancreas-specific irAE is a rare but special one with a variety of manifestations, such as pancreatic enzymes elevation, pancreatitis as well as diabetes. The current study reported 22 pancreas-specific irAEs in 21 patients with lung cancer, including pancreatic injury in 13 patients, pancreatitis in four patients and diabetes mellitus in five patients.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"715-722"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents. 原发性免疫缺陷患者赋权计划可提高儿童和青少年的生活质量。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/1750743X.2024.2367924
Maria Fasshauer, Gesine Schuermann, Norbert Gebert, Horst von Bernuth, Monika Bullinger, Sigune Goldacker, Renate Krueger, Petra Manzey, Stefanie Messner, Ellen D Renner, Henrike Ritterbusch, Uwe Schauer, Ilka Schulze, Volker Umlauf, Steffi Widmann, Ulrich Baumann
{"title":"A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents.","authors":"Maria Fasshauer, Gesine Schuermann, Norbert Gebert, Horst von Bernuth, Monika Bullinger, Sigune Goldacker, Renate Krueger, Petra Manzey, Stefanie Messner, Ellen D Renner, Henrike Ritterbusch, Uwe Schauer, Ilka Schulze, Volker Umlauf, Steffi Widmann, Ulrich Baumann","doi":"10.1080/1750743X.2024.2367924","DOIUrl":"10.1080/1750743X.2024.2367924","url":null,"abstract":"<p><p><b>Aim:</b> To assess a patient empowerment program (PEP) for children/adolescents with primary immunodeficiency (PID) on IgG replacement therapy regarding quality of life (QoL) in patients and proxy.<b>Patients & methods:</b> Health-related QoL was assessed using KIDSCREEN-27 and DISABKIDS-37 before and 6 months after PID-PEP kids in 19 children/adolescents and their parents.<b>Results:</b> The following three dimensions of the KIDSCREEN-27 significantly increased in children/adolescents after PID-PEP kids as compared with baseline: Psychological Well-Being, Parents & Autonomy and School Environment. Total DISABKIDS-37 index, as well as 5 of the 6 DISABKIDS-37 dimensions, significantly increased, in other words, Independence, Emotion, Social Inclusion, Social Exclusion and Physical. Evaluation of proxy instruments showed comparable results.<b>Conclusion:</b> PID-PEP kids significantly improved QoL in patients with PID.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"813-819"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review. C5 抑制剂 avacincaptad pegol 治疗地理萎缩：全面回顾。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/1750743X.2024.2368342
Carl J Danzig, Arshad M Khanani, Anat Loewenstein
{"title":"C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review.","authors":"Carl J Danzig, Arshad M Khanani, Anat Loewenstein","doi":"10.1080/1750743X.2024.2368342","DOIUrl":"10.1080/1750743X.2024.2368342","url":null,"abstract":"<p><p>Geographic atrophy (GA) remains a leading cause of central vision loss with no known cure. Until recently, there were no approved treatments for GA, often resulting in poor quality of life for affected patients. GA is characterized by atrophic lesions on the retina that may eventually threaten the fovea. Emerging treatments have demonstrated the ability to reduce the rate of lesion growth, potentially preserving visual function. Avacincaptad pegol (ACP; Astellas Pharma Inc), a complement component 5 inhibitor, is an FDA-approved treatment for GA that has been evaluated in numerous clinical trials. Here we review the current clinical trial landscape of ACP, including critical <i>post hoc</i> analyses that suggest ACP may reduce the risk of severe loss among patients with GA.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"779-790"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study. Meet-URO 15 研究中基于红细胞的转移性 RCC 患者预后评分。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-06 DOI: 10.1080/1750743X.2024.2382666
Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, Giuseppe Fornarini, Marco Maruzzo, Paolo Andrea Zucali, Fabio Catalano, Ludovica Antonj, Marianna Tudini, Lucia Fratino, Andrea Malgeri, Pasquale Rescigno, Alessio Signori, Alessandro Acunzo, Enrico Maria Silini, Giulia Mazzaschi, Sebastiano Buti
{"title":"A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.","authors":"Shobana Anpalakhan, Giuseppe Luigi Banna, Sara Elena Rebuzzi, Giuseppe Fornarini, Marco Maruzzo, Paolo Andrea Zucali, Fabio Catalano, Ludovica Antonj, Marianna Tudini, Lucia Fratino, Andrea Malgeri, Pasquale Rescigno, Alessio Signori, Alessandro Acunzo, Enrico Maria Silini, Giulia Mazzaschi, Sebastiano Buti","doi":"10.1080/1750743X.2024.2382666","DOIUrl":"10.1080/1750743X.2024.2382666","url":null,"abstract":"<p><p><b>Aims:</b> Anemia, mean corpuscular volume and red cell distribution width may have some effects on survival outcomes of metastatic renal cell carcinoma (mRCC) patients and are incorporated in a red blood cell (RBC)-based score. Its validity in prognostication of mRCC patients treated with second-line nivolumab was assessed.<b>Patients and methods:</b> Retrospective analysis using Meet-URO-15 cohort of mRCC patients receiving nivolumab in the second-line setting or beyond. Outcomes were overall survival (OS) and progression-free survival (PFS).<b>Results:</b> A total of 390 patients were included. Significant differences in OS and PFS between RBC-based score groups, with group 1 (2 or 3 of the RBC-related prognostic factors) having longer OS (median 29.5 months, 95% CI: 23.1-35.9, versus 11.5 months, 95% CI: 8.5-22.6; <i>p</i> < 0.001) and PFS (7.5 months, 95% CI: 5.5-10.2, versus 4.2 months, 95% CI: 3.3-5.9; <i>p</i> = 0.040) than those in group 0 (0 or 1 RBC-related prognostic factors). Belonging to group 1 independently predicted OS (hazard ratio: 0.65, 95% CI: 0.50-0.85; <i>p</i> = 0.002) but not PFS (hazard ratio: 0.89, 95% CI: 0.70-1.14, <i>p</i> = 0.370) or disease response (OR 0.68, 95% CI: 0.41-1.10; <i>p</i> = 0.118) at multivariable analysis.<b>Conclusion:</b> RBC-based group scores independently predicted OS in mRCC patients treated with nivolumab.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"963-973"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice. 佐剂 ArtinM 有利于 C57BL/6 小鼠宿主对加滕隐球菌感染的免疫力。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI: 10.1080/1750743X.2024.2360384
Patrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, Michele Procópio Machado, Letícia Costa Serafim, Javier Emílio Lazo Chica, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva
{"title":"Adjuvant ArtinM favored the host immunity against <i>Cryptococcus gattii</i> infection in C57BL/6 mice.","authors":"Patrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, Michele Procópio Machado, Letícia Costa Serafim, Javier Emílio Lazo Chica, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva","doi":"10.1080/1750743X.2024.2360384","DOIUrl":"10.1080/1750743X.2024.2360384","url":null,"abstract":"<p><p><b>Aim:</b> <i>Cryptococcus gattii</i> causes a severe fungal infection with high mortality rate among immunosuppressed and immunocompetent individuals. Due to limitation of current antifungal treatment, new immunotherapeutic approaches are explored.<b>Methods:</b> This study investigated an immunization strategy utilizing heat-inactivated <i>C. gattii</i> with ArtinM as an adjuvant. C57BL/6 mice were intranasally immunized with heat-killed <i>C. gattii</i> and ArtinM was administrated either before immunization or along with HK-<i>C. gattii</i>. Mice were infected with <i>C. gattii</i> and the efficacy of the immunization protocol was evaluated.<b>Results:</b> Mice that received ArtinM exhibited increased levels of IL-10 and relative expression of IL-23 in the lungs, reduced fungal burden and preserved tissue integrity post-infection.<b>Conclusion:</b> Adjuvant ArtinM improved immunization against <i>C. gattii</i> infection in C57BL/6 mice.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"733-748"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis. 过敏性鼻炎患儿间断皮下免疫疗法的新剂量调整方案。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-03 DOI: 10.1080/1750743X.2024.2365619
Min Pan, Jianrong Xue
{"title":"A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis.","authors":"Min Pan, Jianrong Xue","doi":"10.1080/1750743X.2024.2365619","DOIUrl":"10.1080/1750743X.2024.2365619","url":null,"abstract":"<p><p><b>Aim:</b> To assess the effectiveness and safety of a new protocol for adjusting doses during interrupted subcutaneous immunotherapy maintenance, exceeding an 8-week interval, with mite allergen injections in children with allergic rhinitis.<b>Patients & methods:</b> 194 children with allergic rhinitis who underwent subcutaneous immunotherapy and experienced interruptions lasting more than 8 weeks during maintenance were enrolled. Following the adoption of a novel dose-adjustment protocol, a real-world study was conducted.<b>Results:</b> After 3 years of subcutaneous immunotherapy, the novel group exhibited a significant reduction in allergy symptoms compared with baseline. Systemic reactions related to the novel protocol did not significantly increase.<b>Conclusion:</b> The novel protocol was deemed safe and effective, offering advantages of time savings and reduced burdens.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"749-758"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation. 免疫检查点抑制剂治疗微卫星不稳定性阳性、短串联重复突变模式不典型的胰腺癌失败。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-23 DOI: 10.1080/1750743X.2024.2376516
Anna Babayan, Evgeny Ledin, Alexandra Lebedeva, Olesya Kuznetsova, Daria Kravchuk, Tatiana Grigoreva, Ekaterina Belova, Alexandra Kavun, Vladislav Mileyko, Alexey Tryakin, Mikhail Fedyanin, Maxim Ivanov
{"title":"Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation.","authors":"Anna Babayan, Evgeny Ledin, Alexandra Lebedeva, Olesya Kuznetsova, Daria Kravchuk, Tatiana Grigoreva, Ekaterina Belova, Alexandra Kavun, Vladislav Mileyko, Alexey Tryakin, Mikhail Fedyanin, Maxim Ivanov","doi":"10.1080/1750743X.2024.2376516","DOIUrl":"10.1080/1750743X.2024.2376516","url":null,"abstract":"<p><p>Microsatellite instability (MSI) is an important biomarker in cancer. While routine methods can detect MSI in certain tumor types, in other tumor types the results may be incorrect due to differences in the MSI loci pattern. Here, we report the case of a patient with pancreatic adenocarcinoma, with confirmed MSI by two independent next-generation sequencing tests, but not by routine methods, who had progression on pembrolizumab. Comparison of the patient's MSI loci patterns with MSI+ colorectal adenocarcinoma samples showed a lower fraction of unstable loci, low resolution of a second peak in the repeat length spectrum of unstable short tandem repeats in the patient's sample, and a lower length of indels (3.7 vs 4.5 base pairs, <i>p</i> < 0.01).</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"853-858"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular interactions of antibodies with PD-1/PD-L1 proteins. 抗体与 PD-1/PD-L1 蛋白的分子相互作用。
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2023-12-06 DOI: 10.2217/imt-2023-0165
Sofia Vasilakaki, Ioannis Vathiotis, Emmanouil Panagiotou, Evangelos Dimakakos, Georgia Gomatou, Elias Kotteas
{"title":"Molecular interactions of antibodies with PD-1/PD-L1 proteins.","authors":"Sofia Vasilakaki, Ioannis Vathiotis, Emmanouil Panagiotou, Evangelos Dimakakos, Georgia Gomatou, Elias Kotteas","doi":"10.2217/imt-2023-0165","DOIUrl":"10.2217/imt-2023-0165","url":null,"abstract":"<p><p><b>Aim:</b> To compare the protein-protein interactions of antibodies targeting PD-1 and its ligand (PD-L1) with their targets in an attempt to explain the antibodies' binding affinity. <b>Materials & methods:</b> The structural features of complexes between pembrolizumab, nivolumab, durvalumab, atezolizumab, avelumab and PD-1/PD-L1 are described, with the use of software and based on crystallographic data. <b>Results:</b> Pembrolizumab has more structural features, including the number and type of the bonds and total binding surface area, which could rationalize its different clinical behavior compared with nivolumab. Similarly, protein-protein interactions with PD-L1 differ among durvalumab, atezolizumab and avelumab. <b>Conclusion:</b> Differential protein-protein interactions between antibodies and PD-1/PD-L1 may indicate differential clinical activity; however, further research is needed to provide evidence.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"21-28"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信